-
1 Comment
Aarti Drugs Limited is currently in a long term uptrend where the price is trading 1.8% above its 200 day moving average.
From a valuation standpoint, the stock is 35.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Aarti Drugs Limited's total revenue rose by 12.0% to $5B since the same quarter in the previous year.
Its net income has increased by 144.9% to $680M since the same quarter in the previous year.
Finally, its free cash flow fell by 42.8% to $583M since the same quarter in the previous year.
Based on the above factors, Aarti Drugs Limited gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NSE |
| CurrencyCode | INR |
| ISIN | INE767A01016 |
| PE Ratio | 21.6 |
|---|---|
| Target Price | 465 |
| Market Cap | 33B |
| Beta | 0.7 |
| Dividend Yield | 0.3% |
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AARTIDRUGS.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
